| Inequities in access to biologic and synthetic DMARDs across 46 European countries P Putrik, S Ramiro, TK Kvien, T Sokka, M Pavlova, T Uhlig, A Boonen, ... Annals of the rheumatic diseases 73 (1), 198-206, 2014 | 390 | 2014 |
| Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky British journal of dermatology 175 (3), 561-571, 2016 | 238 | 2016 |
| Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries V Brodszky, P Baji, O Balogh, M Péntek The European Journal of Health Economics 15, 65-71, 2014 | 162 | 2014 |
| EQ-5D in central and Eastern Europe: 2000–2015 F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ... Quality of Life Research 25, 2693-2710, 2016 | 146 | 2016 |
| Biosimilars for the management of rheumatoid arthritis: economic considerations L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek Expert review of clinical immunology 11 (sup1), 43-52, 2015 | 125 | 2015 |
| Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? P Putrik, S Ramiro, TK Kvien, T Sokka, T Uhlig, A Boonen, ... Annals of the rheumatic diseases 73 (11), 2010-2021, 2014 | 122 | 2014 |
| Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003 M Péntek, C Horváth, I Boncz, Z Falusi, E Tóth, A Sebestyen, I Májer, ... Osteoporosis international 19, 243-249, 2008 | 117 | 2008 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ... The European Journal of Health Economics 15, 111-119, 2014 | 101 | 2014 |
| A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016 | 94 | 2016 |
| Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 85 | 2020 |
| Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe M Cavazza, Y Kodra, P Armeni, M De Santis, J López-Bastida, ... The European Journal of Health Economics 17, 19-29, 2016 | 85 | 2016 |
| Adherence to biologic DMARD therapies in rheumatoid arthritis T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi Expert opinion on biological therapy 10 (9), 1367-1378, 2010 | 84 | 2010 |
| The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek Advances in Therapy 34, 1128-1144, 2017 | 82 | 2017 |
| Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A ¦liwczyński, ... World Journal of Gastroenterology: WJG 21 (6), 1728, 2015 | 82 | 2015 |
| Cost-of-illness of patients with systemic sclerosis in a tertiary care centre T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgar, L Czirjak, ... Rheumatology 49 (10), 1920-1928, 2010 | 77 | 2010 |
| Assessment of skin involvement in systemic sclerosis G Kumánovics, M Péntek, S Bae, D Opris, D Khanna, DE Furst, L Czirják Rheumatology 56 (suppl_5), v53-v66, 2017 | 74 | 2017 |
| Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment V Brodszky, P Bálint, P Géher, L Hodinka, G Horváth, É Koó, M Péntek, ... Rheumatology international 30, 199-205, 2009 | 70 | 2009 |
| Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients AK Poór, F Rencz, V Brodszky, L Gulácsi, Z Beretzky, B Hidvégi, P Holló, ... Quality of Life Research 26, 3409-3419, 2017 | 69 | 2017 |
| A detailed analysis of ‘not relevant’responses on the DLQI in psoriasis: potential biases in treatment decisions F Rencz, AK Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, ... Journal of the European Academy of Dermatology and Venereology 32 (5), 783-790, 2018 | 68 | 2018 |
| Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe A Kuhlmann, T Schmidt, M Treskova, J Lopez-Bastida, R Linertova, ... The European Journal of Health Economics 17, 79-87, 2016 | 68 | 2016 |
Prof. László Gulácsi, DScBudapest, Hungary, Óbuda UniversityE-mail megerősítve itt: uni-obuda.hu
